Invasive pulmonary aspergillosis complicating neoplastic disease.
Invasive pulmonary aspergillosis is a necrotizing pneumonia that is most frequently seen in association with profound granulocytopenia as a consequence of cytotoxic chemotherapy that is used to treat hematologic neoplasms. There is considerable evidence that the incidence of this infection is increasing over the past decade as a result of improved medical support used in the management of "at risk" patients. Heightened clinical awareness coupled with advances in diagnostic techniques have led to earlier treatment and improved outcomes of this once uniformly fatal infection. Amphotericin B remains the treatment of choice; however, newer therapeutics (azoles) and strategies (combination chemotherapy, biological response modifiers) show promise as alternative regimens. Novel approaches in preventing the acquisition of pulmonary aspergillosis in the "at risk" patient are being explored.
Pursell
K J
KJ
Infectious Disease Service, University of Illinois, Chicago, IL 60612.
D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D001230:Aspergillus / Q000472:pathogenicity; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D009369:Neoplasms / Q000150:complications; D011379:Prognosis; D012307:Risk Factors
D000935:Antifungal Agents; D000970:Antineoplastic Agents